NEW YORK (GenomeWeb News) – Autoimmune molecular diagnostics firm Ignyta today said it is working with Leiden University Medical Center to evaluate epigenetic signatures of patients with early synovitis and rheumatoid arthritis.
FlexGen of the Netherlands said last week that China's BGI and Leiden University Medical Center will use its target enrichment technology to validate variants for the Genome of the Netherlands, or GoNL, project.
The sale follows a collaboration between Helicos and Leiden University Medical Center's forensic laboratory, which provided the company with DNA from human remains for analysis, a project the partners plan to publish.
Researchers in the Neuromuscular Disorder-Chip Consortium will use custom-designed NimbleGen Human CGH 12x135K microarrays and Human Sequence Capture 385K arrays to study the genetic underpinnings of a range of neuromuscular disorders.
The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.